Zevra Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Zevra Therapeutics, Inc. (NASDAQ: ZVRA), formerly known as KemPharm, Inc., is a commercial-stage rare disease biopharmaceutical company headquartered in Celebration, Florida. The company has successfully transitioned from a prodrug-development platform into a focused rare-disease commercial and development entity. Zevra's commercial portfolio is anchored by MIPLYFFA (arimoclomol), an FDA-approved treatment for the neurological manifestations of Niemann-Pick disease type C (NPC), and OLPRUVA (sodium phenylbutyrate) for urea cycle disorders (UCDs). Additionally, the company receives royalty revenue from AZSTARYS, an ADHD treatment commercialized by its partner Corium.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Maximizing the commercial launch of MIPLYFFA (arimoclomol) in the U.S. for Niemann-Pick disease type C (NPC) by expanding prescriber awareness, increasing patient enrollment forms, and maintaining stable market access (covering 69% of covered lives as of Q1 2026).
Expected impact: Driving sustainable, high-margin product revenue to establish a strong corporate foundation and fund pipeline development.
Consolidating development and scientific functions under the Chief Medical Officer, eliminating in-house drug discovery, closing laboratory facilities in Iowa and Virginia, and outsourcing early R&D to minimize costs and focus resources on late-stage clinical and commercial opportunities.
Expected impact: Reduced general and administrative spending, lower R&D overhead, and improved capital efficiency.
Restarting and accelerating patient enrollment in the Phase 3 DiSCOVER trial of celiprolol for Vascular Ehlers-Danlos Syndrome (VEDS) under a Special Protocol Assessment (SPA) agreement with the FDA.
Expected impact: Advancing the clinical development of celiprolol toward the target of 150 enrolled patients and 46 qualifying events to support FDA approval.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired to transform Zevra from a prodrug-focused developer into a commercial-stage rare disease company. The transaction added OLPRUVA (for urea cycle disorders), the celiprolol program for VEDS, and arimoclomol (MIPLYFFA) for NPC.
Financial impact: Propelled Zevra into the commercial stage, diversifying its revenue streams and providing the pipeline assets that drove a 351% revenue acceleration in FY2025.
Strategic Partnerships
Enables Niemann-Pick Disease Type C (NPC) patients to access MIPLYFFA (arimoclomol) through reimbursed named-patient supply in select territories outside of Europe, leveraging Uniphar's global warehousing, distribution, and supply chain management infrastructure.
Terms: Reimbursed named-patient supply terms; specific financial details were not disclosed.
Commave purchased Zevra's entire serdexmethylphenidate (SDX) portfolio, including AZSTARYS and KP1077, which resolved outstanding Delaware Chancery Court litigation and allowed Zevra to monetize non-core assets and focus exclusively on rare diseases.
Terms: Commave purchased the portfolio for $50 million in cash.